XsunX, Inc. has developed and begun to market a hybrid manufacturing solution to produce high performance Copper Indium Gallium di Selenide CIGS thin film solar cells. Our patent pending deposition system and thermal evaporation processing technology, which we call CIGSolar TM , focuses on the mass production of individual thin film CIGS solar cells that match silicon solar cell dimensions and can be offered as a high efficiency, capital efficient, lowest cost alternative to the use of silicon solar cells. lt br / gt lt br / gt We are offering licenses for the use of the CIGSolar TM process technology through which we will generate revenue on equipment, licensing fees, and long term manufacturing royalty revenues. lt br / gt lt br / gt Our thin film CIGSolar TM cells are the first solar cell technology to target an existing multi billion dollar silicon solar cell supply chain as a less costly alternative. The CIGSolar TM solution offers the potential to revolutionize the solar industry offering the highest yield CIGS manufacturing technology available in the market today. lt br / gt lt br / gt XsunX Technology Advantage lt br / gt lt br / gt The US National Renewable Energy Laboratories NREL recently certified peak conversion efficiency of . with an overall average of . for XsunX CIGSolar TM samples. The key to delivering this potential is an innovative new approach that bridges the gap between inexpensive thin film and high efficiency silicon wafer technologies to produce a new breed of solar cells combining the best attributes of each technology.
Quote | Xsunx Inc (OTCMKTS:XSNX)
Last: | $0.0139 |
---|---|
Change Percent: | 0.0% |
Open: | $0.0139 |
Close: | $0.0139 |
High: | $0.0139 |
Low: | $0.0139 |
Volume: | 80,678 |
Last Trade Date Time: | 07/16/2024 03:00:00 am |
News | Xsunx Inc (OTCMKTS:XSNX)
CLEVELAND, OH / ACCESSWIRE / May 21, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a pioneering biomedical company developing innovative immunotherapies for brain tumor patients, today announced it has submitted a provisional patent for new intellectual property developed at Cedars-Sinai to advance...
CLEVELAND, OH / ACCESSWIRE / May 7, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced the postponement of its Annual Meeting of Shareholder which was previously scheduled to be held in May 2024. The Company ...
Message Board Posts | Xsunx Inc (OTCMKTS:XSNX)
Subject | By | Source | When |
---|---|---|---|
Looks good today on low vol, watching | InvestorNews1 | investorshub | 02/15/2023 8:25:32 PM |
Unfortunately... | splintered sunlight | investorshub | 01/26/2023 4:52:23 PM |
Looks like $XSNX is owning up to owing | BooDog | investorshub | 01/26/2023 4:09:49 PM |
What do you make of this? | splintered sunlight | investorshub | 01/24/2023 2:17:48 PM |
8K yesterday..... | splintered sunlight | investorshub | 01/24/2023 1:53:03 PM |
News, Short Squeeze, Breakout and More Instantly...
CLEVELAND, OH / ACCESSWIRE / May 21, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a pioneering biomedical company developing innovative immunotherapies for brain tumor patients, today announced it has submitted a provisional patent for new intellectual property developed at Cedars-Sinai to advance...
CLEVELAND, OH / ACCESSWIRE / May 7, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced the postponement of its Annual Meeting of Shareholder which was previously scheduled to be held in May 2024. The Company ...
CLEVELAND, OH / ACCESSWIRE / April 30, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing a novel immunotherapy for patients suffering from cancers of the central nervous system, today announced the procurement of a new intellectual property license from Cedars-Sinai Medi...